Vanguard Group Inc Neoleukin Therapeutics, Inc. Transaction History

Vanguard Group Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.68 - $0.91 $3,729 - $4,990	-5,484 Reduced 0.54%	1,010,812 $838,000
Q4 2022 Feb 10, 2023	SELL	$0.4 - $0.55 $3,836 - $5,274	-9,590 Reduced 0.93%	1,016,296 $518,000
Q3 2022 Nov 14, 2022	SELL	$0.69 - $1.33 $67,150 - $129,434	-97,319 Reduced 8.66%	1,025,886 $657,000
Q2 2022 Aug 12, 2022	SELL	$0.92 - $2.25 $144,712 - $353,916	-157,296 Reduced 12.28%	1,123,205 $1.16 Million
Q1 2022 May 13, 2022	SELL	$1.72 - $5.23 $549,543 - $1.67 Million	-319,502 Reduced 19.97%	1,280,501 $2.41 Million
Q4 2021 Feb 14, 2022	SELL	$4.65 - $7.75 $49,145 - $81,909	-10,569 Reduced 0.66%	1,600,003 $7.71 Million
Q3 2021 Nov 12, 2021	BUY	$6.05 - $9.66 $102,789 - $164,123	16,990 Added 1.07%	1,610,572 $11.6 Million
Q2 2021 Aug 13, 2021	BUY	$9.23 - $13.12 $14.7 Million - $20.9 Million	1,593,582 New	1,593,582 $14.7 Million

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.